Question special
Faculty

Looking through the subgroup analyses in the appendix, I was surprised by the findings for patients over 80 on 150 mg of dabigatran dual-therapy. Granted the numbers of patients are very small (8 patients), but I'm interested to hear the authors thoughts about these results.